Skip to main content

Table 4 Adverse effects

From: Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients

Adverse effect

Heart transplant recipients (n = 78)

Non-transplant patients (n = 156)

p value

Death, n (%)

0

0

N/A

Asystole, n (%)

0

0

N/A

Sinus pause or arrest, n (%)

0

0

N/A

High-grade atrioventricular block, n (%)

0

0

N/A

Ventricular tachycardia or ventricular fibrillation, n (%)

0

0

N/A

Atrial fibrillation, n (%)

0

0

N/A

Chest pain requiring sublingual nitroglycerin, n (%)

1 (1)

0

0.33

Myocardial infarction, n (%)

0

0

N/A

Symptomatic hypotension, n (%)

1 (1)

1 (0.6)

0.65

Dyspnea, n (%)

6 (7)

9 (6)

0.58

Nausea, n (%)

6 (7)

3 (2)

0.08

Headache, n (%)

2 (3)

0

0.11

Allergic reaction (rash, hives, etc.), n (%)

0

0

N/A

Contrast extravasation, n (%)

0

2 (1)

0.55

Thrombophlebitis, n (%)

0

0

N/A

Hospitalization, n (%)

0

0

N/A